Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00521885 · ClinicalTrials.gov registry record · NA
Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients
A NA study, sponsored by Lehigh Valley Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT00521885 is a NA study that was terminated before completion, run by Lehigh Valley Hospital. The registered enrollment target is 1 participants.
The verdict
NCT00521885, a NA study, was terminated before completion, sponsored by Lehigh Valley Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
A total of 50 patients \>40 yrs of age with an expected hospital stay in the Medical Intensive Care or Regional Heart Unit at LVH Muhlenberg of 6 days or longer will be enrolled. The patient and study team will be blinded to which drug they are receiving (either Arixtra or Lovenox). Subjects will be examined for any bleeding complications. Subjects will receive drug for a total of 6-14 days while in the hospital. A follow up phone call will be performed by the study team approximately 30 days after discharge from the hospital.
Interventions
- DRUG Arixtra (Fondaparinox) 2.5 mg SC Daily
- DRUG Lovenox 40mg SC Daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00521885
The ClinicalTrials.gov registry entry for NCT00521885 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lehigh Valley Hospital, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Arixtra (Fondaparinox) 2.5 mg SC Daily is the first listed.
NCT00521885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00521885 about?
NCT00521885 is a clinical study titled "Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients". A total of 50 patients \>40 yrs of age with an expected hospital stay in the Medical Intensive Care or Regional Heart Unit at LVH Muhlenberg of 6 days or longer will be enrolled. The patient and study team will be blinded to which drug they are receiving (either Arixtra or Lovenox). Subjects will be...
What is the current status of trial NCT00521885?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2007-09. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00521885?
The interventions under investigation include: Arixtra (Fondaparinox) 2.5 mg SC Daily (DRUG), Lovenox 40mg SC Daily (DRUG).
Who is sponsoring clinical trial NCT00521885?
This trial is sponsored by Lehigh Valley Hospital, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.